Lipocine Inc. (LPCN) financial statements (2021 and earlier)

Company profile

Business Address 675 ARAPEEN DRIVE, SUITE 202
SALT LAKE CITY, 84108
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments2014821274428
Cash and cash equivalents19108362028
Short-term investments04 182124 
Receivables000300 
Other undisclosed current assets66130000
Total current assets:25202125274528
Noncurrent Assets
Property, plant and equipment 000000
Long-term investments and receivables     0 
Long-term investments     0 
Other noncurrent assets0000000
Total noncurrent assets:0000000
TOTAL ASSETS:25202125274528
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities3212132
Accounts payable2111010
Accrued liabilities2001131
Debt333    
Estimated litigation liability   4   
Total current liabilities:7546132
Noncurrent Liabilities
Long-term debt and lease obligation247    
Long-term debt, excluding current maturities247    
Other undisclosed noncurrent liabilities15     
Total noncurrent liabilities:387    
Total liabilities:1013116132
Stockholders' equity
Stockholders' equity attributable to parent156919264226
Common stock0000000
Treasury stock, value(0)(0)(0)(0)(0)(0)(0)
Additional paid in capital18715714814513112995
Accumulated other comprehensive loss (0)(0)(0)(0)(0) 
Accumulated deficit(172)(151)(138)(126)(105)(86)(68)
Total stockholders' equity:156919264226
TOTAL LIABILITIES AND EQUITY:25202125274528

Income statement (P&L) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Gross profit: 00    
Operating expenses(18)(13)(12)(21)(19)(18)(20)
Other operating income, net      0
Other undisclosed operating loss      (0)
Operating loss:(18)(13)(11)(21)(19)(18)(20)
Nonoperating expense
(Other Nonoperating expense)
(3)(0)(0)    
Interest and debt expense0      
Other undisclosed income (loss) from continuing operations before equity method investments, income taxes(0)0 0000
Loss from continuing operations before income taxes:(21)(13)(12)(21)(19)(18)(20)
Income tax expense(0)(0)(0)(0)(0)(0)(0)
Net loss available to common stockholders, diluted:(21)(13)(12)(21)(19)(18)(20)

Comprehensive Income ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Net loss:(21)(13)(12)(21)(19)(18)(20)
Comprehensive loss:(21)(13)(12)(21)(19)(18)(20)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent00000(0) 
Comprehensive loss, net of tax, attributable to parent:(21)(13)(12)(21)(19)(18)(20)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: